Home News and Events

News and Events

  1. AST welcomes David Sneider to Board of Directors

    Aurora Spectral Technologies, LLC is pleased to announce that as of March 1, 2013, Mr. David C. Sneider has been elected as a member of the Board of Directors. Mr. Sneider has served in an advisory role to the Board of Directors during the past year, and with this appointment, AST secures David’s continued contribution to the Company.

    David Sneider is a seasoned financial executive who, during his career, contributed significantly to the financial success of many early start-ups, taking them to successful exits including IPO.

    Most recently Mr. Sneider served as Vice President and Chief Financial Officer of Nerites Corporation, a venture capital financed company which developed medical devices to aid tissue repair, speed surgical times and reduce postoperative complications. During Mr. Sneider’s tenure, Nerites raised in excess of $12,000,000. Nerites was acquired in 2011 by Kensey Nash Corporation.

    From 2006 until 2008, Mr. Sneider served as Vice President and Chief Business Officer of Cellular Dynamics International, Inc. Cellular Dynamics products provide industrialized quantities of genetically diverse, terminally differentiated human cells enabling basic research, efficient drug discovery programs and reliably predictive toxicity and efficacy screening through in vitro clinical trials. Previously, Mr. Sneider had been Vice President and Chief Financial Officer of NimbleGen Systems Inc from 2000 to 2006. NimbleGen was acquired by Roche Diagnostics for $272 million. Before that Mr. Sneider was the Chief Financial Officer and Secretary of Third Wave Technologies, Inc. (TWTI: NASDAQ), from 1997 to 2000. Earlier in his career, Mr. Sneider was Chief Financial Officer, Secretary and Treasurer of Tellabs, Inc. (TLAB: NASDAQ) where he oversaw two public stock offerings including its initial public offering.

    Currently, Mr. Sneider serves as advisor to Flex Biomedical, Inc. which is developing novel treatments and diagnostics for orthopedic diseases and as a board member of Sonoplot, Inc. which provides fluid dispensers and chemical surface treatments for microelectronics and the life sciences. Both companies are financed by angel investors.

    In joining the board here at Aurora Spectral Technologies, Mr. Sneider will lend his considerable business and financial expertise to support Aurora Spectral Technologies as it begins the introduction of OptiMiS TruLine micro-spectroscopy system to scientists throughout the world.

  2. AST welcomes Dr. Jolien Connor

    Aurora Spectral Technologies is pleased to welcome Dr. Jolien Connor to the position of Technical and Applications Scientist.

    Dr. Connor earned her PhD in Neuoroscience at the University of Wisconsin-Madison, working with transgenic mice in the area of potassium channels. During and after her doctorate, Jolien gravitated towards microscopy, including brightfield, fluorescence, confocal and some work with multi-photon systems. She served as the facility manager of the Waisman Cellular and Molecular Neurosciences Core, which employed a Nikon C1 confocal system and a Zeiss stereology and fluorescence system along with other types of research equipment. Jolien continues to be involved in a variety of biological research projects, but her passion lies in microscopy.

    In her role here at Aurora Spectral Technologies, one of Dr. Connor’s goals will be applying the advanced capabilities of the OptiMiS spectral scanning system to address several significant challenges in biological imaging today. Many people are likely to meet or speak with Jolien as she serves as technical liaison for scientists around the world interested in seeing how the OptiMiS system can be utilized for their research.

    She may be reached at the following:

    Jolien Connor, PhD
    Technical and Applications Scientist
    Aurora Spectral Technologies, LLC
    (414) 416-2550
    jconnor@auroraspectral.com

  3. Download Nov 28th, 2012 Webinar: ‘Studying quaternary protein structure in living cells in real time’

    Recently, Aurora Spectral Technologies sponsored a symposium webinar hosted by Cambridge Healthtech Institute entitled:

    “New Method for Studying Quaternary Structure of GPCR Proteins in vivo in Real Time”

    Symposium Course Description:
    The course provides a summary of the development and utilization of a new spectral imaging system, OptiMiS, to study quaternary protein structure in living cells in real time. The research will detail the use of this new system to determine the quaternary structure of a series of GPCR proteins in the membrane and cytoplasm of cells. Since the time for analysis is on the order of milliseconds, the structure of these proteins can be assessed in ‘real time’ before the impact of diffusion occurs.

    Follow this link to review speaker information and to download webinar presentation.